Valuation: EQL Pharma AB

Market Cap 611M 63.07M 55.27M 51.37M 47.17M 88.85M 6.09B 90.26M 239M 2.98B 237M 232M 10.37B P/E 2026
130x
P/E 2027 * 33.9x
Enterprise Value 927M 95.68M 83.84M 77.93M 71.55M 135M 9.23B 137M 363M 4.52B 359M 351M 15.73B EV / Sales 2026
4.55x
EV / Sales 2027 * 2x
Free-Float
38.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 40 2022-08-16
Director of Finance/CFO 51 2026-03-31
Chief Operating Officer 48 2022-08-16
Director TitleAgeSince
Chairman 61 2022-08-16
Director/Board Member 53 2019-12-31
Chairman 59 -
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%+8.19% - - 63.22M
-0.92%+0.55%-22.37%-8.35% 6.01B
+0.46%+1.92%-8.72%-29.52% 3.88B
-0.32%+4.39%-38.06%-12.17% 3.24B
-0.79%-4.67%+11.34%-30.34% 3.18B
+0.11%-0.05%-30.31%-48.82% 3.16B
-0.25%+3.12%-18.69%+0.66% 2.56B
-2.79%+0.25%+90.38% - 2.59B
-0.09%-1.05%+1.58%+37.44% 1.67B
-1.02%+2.79%-36.00%-34.46% 1.58B
Average -0.72%+0.94%-5.65%-15.70% 3.1B
Weighted average by Cap. -0.60%+0.90%-7.86%-17.60%

Financials

2026 2027 *
Net sales 429M 44.27M 38.79M 36.05M 33.1M 62.36M 4.27B 63.34M 168M 2.09B 166M 162M 7.28B 495M 51.08M 44.75M 41.6M 38.2M 71.95M 4.93B 73.09M 194M 2.42B 192M 187M 8.4B
Net income 20M 2.06M 1.81M 1.68M 1.54M 2.91M 199M 2.95M 7.82M 97.6M 7.75M 7.58M 339M 18M 1.86M 1.63M 1.51M 1.39M 2.62M 179M 2.66M 7.04M 87.84M 6.97M 6.82M 305M
Net Debt 316M 32.61M 28.57M 26.56M 24.38M 45.93M 3.15B 46.66M 124M 1.54B 122M 120M 5.36B 381M 39.31M 34.45M 32.02M 29.4M 55.38M 3.79B 56.26M 149M 1.86B 148M 144M 6.46B
Logo EQL Pharma AB
EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.
Employees
-
Trader
Investor
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise